LANLUMA

LANLUMA at a Glance

LANLUMA is a collagen-stimulating injectable made from poly-L-lactic acid (PLLA), designed for facial and body sculpting. It provides long-lasting volumization by stimulating natural collagen production over time.

• Available in two sizes: LANLUMA V (210 mg) and LANLUMA X (630 mg)
• Class III medical device for subdermal injection
• Results develop gradually and can last up to 2 years
• Clinically proven high patient satisfaction and low downtime
• Manufactured and supported by Sinclair Pharma, with comprehensive clinician training and marketing support

LANLUMA Clinical Advantages and Outcomes

LANLUMA delivers consistent clinical performance through safe, gradual biostimulation. It provides natural contouring, volume restoration, and skin texture improvement in targeted areas.

• PLLA microparticles stimulate fibroblasts to regenerate collagen over time
• Gradual onset reduces overfilling risk; results evolve over 6–12 weeks
• Patients typically require 1–4 sessions depending on area and volume
• Effective in both superficial and deep subdermal planes
• Ideal for aesthetic results that are long-lasting and low-maintenance

About LANLUMA Sterican Needles

The product is delivered using needle or cannula injection techniques, depending on treatment area. Each format is optimized for precise placement and controlled diffusion.

• Recommended for use with standard sterile needles or cannulas
• Injection technique (needle vs. cannula) tailored by region: facial vs. gluteal
• Backed by clinical injection protocols and video training from Sinclair College
• Designed for minimal clogging during administration

LANLUMA Target Areas and Patient Profiles

LANLUMA is suited for adult patients seeking minimally invasive rejuvenation or body contour enhancement. Its versatility allows application across both aesthetic and corrective indications.

Common treatment zones:

• Face: cheeks, temples, jawline, chin, nasolabial folds (avoid lips and orbital areas)
• Body: buttocks, thighs, arms, neck, décolletage
• Hands: for rejuvenation and volume replenishment

Ideal candidates include:

• Patients seeking natural-looking facial restoration
• Individuals with volume loss, postpartum changes, or age-related atrophy
• Clients looking to address skin laxity, cellulite, or contour irregularities

LANLUMA Composition and Active Mechanism

LANLUMA’s performance is driven by PLLA (poly-L-lactic acid), a biodegradable, biocompatible, and immunologically inert polymer used safely in medicine for over 30 years.

• LANLUMA V: 210 mg PLLA per vial – ideal for facial rejuvenation
• LANLUMA X: 630 mg PLLA per vial – ideal for body sculpting
• PLLA belongs to the alpha-hydroxy acid family
• Granulometric control ensures particle uniformity and consistent dispersion
• Triggers fibroplasia and gradual volume increase as collagen regenerates
• Completely resorbed over time as natural tissue replaces synthetic filler

LANLUMA Injection Protocol and Techniques

LANLUMA is prepared quickly and injected using well-defined protocols tailored by area. It’s easy to work with, featuring minimal clogging, fast prep, and adaptable volume control.

General steps:

1. Reconstitution: mix PLLA powder with sterile water
2. Injection: place product subdermally using needle or cannula
3. Initial volume fills treated area temporarily
4. Absorption phase clears water, leaving PLLA to stimulate collagen
5. Collagen remodeling begins within 6 weeks

Facial protocol:

• Use LANLUMA V, 1–3 sessions spaced weeks apart
• Treat cheeks, jawline, temples, and nasolabial folds
• Avoid perioral and orbital regions

Buttocks protocol:

• Use LANLUMA X, 1–2 vials per side per session
• 2–4 sessions for reshaping, smoothing, and augmentation
• Avoid use in V-shaped buttocks

LANLUMA Storage, Shelf Life, and Handling

LANLUMA is packaged in sterile single-use vials and offers excellent storage flexibility for clinic workflows.

• Store below 25°C in original packaging
• Shelf life: typically 24–36 months from manufacture
• Prepare product within minutes prior to injection
• Do not reuse partially used vials
• Ensure aseptic technique during reconstitution and injection

LANLUMA Side Effects and Monitoring Considerations

LANLUMA has a well-established safety profile, but practitioners should remain aware of typical injectable risks.

Common side effects:

• Local swelling, redness, or tenderness at injection site
• Temporary asymmetry or lump formation as collagen develops
• Bruising or minor bleeding during or post-injection

Less common risks:

• Granulomas or nodules, typically from improper injection depth or product clumping
• Infection risk if aseptic protocol is not followed
• Avoid injection in or near lips, eyes, or oral commissure – contraindicated areas

Common Practitioner Questions About LANLUMA

How soon do results appear?

• Initial results begin within 6 weeks; full effect seen by 3 months.

How long do results last?

• Clinical outcomes can persist for up to 2 years post-treatment.

What’s the difference between V and X?

• LANLUMA V (210 mg) is for small/facial zones; LANLUMA X (630 mg) is for large/body areas.

How many treatments are required?

• Facial: 1–3 sessions; Buttocks: 2–4 sessions, depending on volume goals.

Is it painful?

• Typically performed under local anesthesia, with most patients returning to normal activity same day.

How to Order LANLUMA for Clinical Use

LANLUMA is available from authorized Sinclair Pharma distributors. Ensure compliance with regional regulations and training requirements.

Order LANLUMA at wholesale prices on Doctor Medica today!